NCT06463379

The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 215 (estimated)
• Sponsor: Sohag University · Academic / Other
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Interventional phase 3 study aiming to unravel the value of pulse steroids in achieving remission or low disease activity in refractory active JIA

Detailed description

First group will receive 2 consecutive days intravenous pulse of 125 mg methylprednisolone. Second group will not receive additional drugs. Assessment was done at baseline and every month for 3 months for both groups using Juvenile Arthritis Disease Activity Score (JADAS) and the American College of Rheumatology Pediatric 30, 50, and 70 response criteria (ACR Pedi. 30, 50, 70).

Conditions

• Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)

Interventions

Type	Name	Description
DRUG	Solumedrol	2 days pulse steroid injection 125 mg methylrednisolone

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-08-31
• Completion: 2024-08-31
• First posted: 2024-06-17
• Last updated: 2024-06-17

Locations

1 site across 1 country: Egypt